statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Small Neurodegenerative Disease-Focused Vigil Neuroscience Says Alzheimer's Candidate Shows Significant Impact On Disease Bimarker

Vigil Neuroscience reports promising interim results from its Phase 1 trial of VG-3927, showing a strong safety, tolerability, and pharmacokinetic profile in healthy volunteers. The data support...

Vigil Neuroscience's Promising Phase 1 Trial and Alzheimer's Focus

Vigil Neuroscience Inc (VIGL) has issued an update. Vigil Neuroscience, Inc. revealed promising interim results from a Phase 1 trial of VG-3927 in...

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL)

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL) SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder...

Vigil Neuroscience, Inc. (NASDAQ:VIGL) Forecasted to Post Q2 2024 Earnings of ($0.58) Per Share

Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) - HC Wainwright issued their Q2 2024 EPS estimates for shares of Vigil Neuroscience in a research note issued on Wednesday, March 27th. HC...

Vigil Neuroscience, Inc. Expected to Earn Q1 2024 Earnings of ($0.58) Per Share (NASDAQ:VIGL)

Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) - Investment analysts at HC Wainwright issued their Q1 2024 EPS estimates for Vigil Neuroscience in a report released on Wednesday, March 27th...

Wedbush Analysts Lower Earnings Estimates for Vigil Neuroscience, Inc. (NASDAQ:VIGL)

Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) - Research analysts at Wedbush lowered their Q1 2024 EPS estimates for shares of Vigil Neuroscience in a report released on Tuesday, March...

Buy Rating Affirmed for Vigil Neuroscience on Promising Clinical Trials and Key Data Readouts

Mizuho Securities analyst Graig Suvannavejh has reiterated their bullish stance on VIGL stock, giving a Buy rating on March 27. Graig Suvannavejh h...

Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Reported positive interim data from Phase 2 IGNITE proof-of-concept clinical trial evaluating iluzanebart (VGL101) for treatment of ALSP Enrollment for IGNITE trial completed with 20 patients...

Vigil Neuroscience GAAP EPS of -$0.57 in-line

Vigil Neuroscience GAAP EPS of -$0.57 in-line...

Buy Rating Affirmed: Vigil Neuroscience's Advancing TREM2 Programs and Strong Financial Position

Vigil Neuroscience Inc (VIGL Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jason Butler...

Vigil Neuroscience, Inc. engages in the provision of biotechnology research services. Its focus is improving the lives of patients, caregivers, and families affected by neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. The company was founded on June 22, 2020 and is headquartered in Watertown, MA.

Volume	348,359.00
52-Wk High	$9.24
52-Wk Low	$2.47

VIGL Vigil Neuroscience Inc

About

Feed

News

Earnings

Fundamentals